First-in-human study for londamocitinib (AZD4604), an inhaled, selective JAK1 inhibitor

Journal:

The Journal of Allergy and Clinical Immunology

Published:

2026-01-13

DOI:

10.1016/j.jaci.2025.12.1008

Affiliations:

19

Authors:

17

Go to article

Institutions	Authors	Share
AstraZeneca Sweden, Sweden	8.500000	0.50
AstraZeneca, United Kingdom (UK)	3.500000	0.21
PAREXEL London, United Kingdom (UK)	1.000000	0.06
Celerion, United Kingdom (UK)	1.000000	0.06
Alexion - Spain, Spain	1.000000	0.06
University of Birmingham, United Kingdom (UK)	0.500000	0.03
Imperial College London (ICL), United Kingdom (UK)	0.500000	0.03
Medicines Evaluation Unit (MEU) Ltd., United Kingdom (UK)	0.333333	0.02
The University of Manchester (UoM), United Kingdom (UK)	0.333333	0.02
Manchester University NHS Foundation Trust (MFT), United Kingdom (UK)	0.333333	0.02

Interested in Immunology?